Keratin 17 is a Diagnostic and Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma

Novel biomarker of decreased survival in patients with squamous cell carcinoma of the tonsils and tongue as well as a diagnostic marker for squamous cell carcinoma of the tonsil, tongue, and larynx. Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide and is diagnosed in more than 600,000 individuals annually. Despite advances in treatment modalities, the prognosis of patients with HNSCC remains poor, with an average five-year survival rate of 40-50%. Currently, human papilloma virus (HPV) status is the only prognostic bio-marker used in clinical practice as an indicator of survival-time from diagnosis of HNSCC, despite the fact that 75% of all HNSCCsare HPV-negative. Thus, there is an unmet need to identify novel prognostic bio-markers that could be used in conjunction with HPV testing to better predict patient outcomes and survival time from initial diagnoses. Technology Overview: Dr. Kenneth Shroyer, Professor and Chair in the Department of Pathology at Stony Brook University processed cases of squamous cell carcinoma (SCC) of the tonsils, larynx, tongue, and normal tissue, by antibody staining for keratin 17 (KRT17), a protein that is normally expressed in some stem cells but not in the normal lining of the mouth, tonsils, and throat. Staining results were compared with patient survival and tissue diagnosis. Furthermore, high levels of KRT17 were significantly associated with decreased patient survival in tonsillar and lingual SCCs, but not laryngeal SCCs. These results indicate that KRT17 could be used to detect SCC of the head and neck, as well as to predict patient survival. Advantages: Novel biomarker of decreased survival for patients with squamous cell carcinoma of the tonsils and tongue Potential diagnostic marker for squamous cell carcinoma of the tonsil, tongue, and larynx Applications: Detection of squamous cell carcinoma of the head and neck Predicting patient survival for patients with squamous cell carcinoma Intellectual Property Summary: PCT Publication No. WO2015-175858 Stage of Development: preclinical Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area Licensing Status: Available for License Additional Information: Keratin 17, Squamous cell carcinoma, Head and neck, Tonsil, Tonge, Larynz https://stonybrook.technologypublisher.com/files/sites/drug-delivery1.jpg , https://stonybrook.technologypublisher.com/files/sites/drug-design-&-synthesis1.jpg , https://stonybrook.technologypublisher.com/files/sites/education-&-training1.jpg
Patent Information:
Technology/Start-up ID: